Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Pharma (IGC) over the last 14 years, with Q3 2025 value amounting to $886000.0.

  • Pharma's Accumulated Expenses fell 5644.05% to $886000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $886000.0, marking a year-over-year decrease of 5644.05%. This contributed to the annual value of $1.4 million for FY2025, which is 1231.65% down from last year.
  • Per Pharma's latest filing, its Accumulated Expenses stood at $886000.0 for Q3 2025, which was down 5644.05% from $792000.0 recorded in Q2 2025.
  • Pharma's 5-year Accumulated Expenses high stood at $2.0 million for Q3 2024, and its period low was $792000.0 during Q2 2025.
  • Moreover, its 3-year median value for Accumulated Expenses was $1.4 million (2025), whereas its average is $1.4 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 4145.96% in 2024, then crashed by 5644.05% in 2025.
  • Pharma's Accumulated Expenses (Quarter) stood at $1.3 million in 2023, then surged by 41.46% to $1.8 million in 2024, then plummeted by 51.37% to $886000.0 in 2025.
  • Its Accumulated Expenses was $886000.0 in Q3 2025, compared to $792000.0 in Q2 2025 and $1.4 million in Q1 2025.